A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Patisiran (Primary)
- Indications Amyloidosis
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 27 Jun 2017 Results of preliminary 24 month data, presented at the 3rd Congress of the European Academy of Neurology.
- 24 May 2017 Results of preliminary 24 month data, presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 28 Apr 2017 Results of the preliminary 24-month data, presented at the 69th Annual Meeting of the American Academy of Neurology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History